TOP 100 MEDICAL SITES
| |||
|
| |||
| |||
|
| |||
| PPD Announces Effectiveness of Furiex Pharmaceuticals' Registration Statement on Form 10 (Business Wire) WILMINGTON, N.C.----PPD, Inc. announced today that, in connection with its proposed spin-off of Furiex Pharmaceuticals, Inc., the Securities and Exchange Commission has declared effective Furiex Pharmaceuticals' Registration Statement on Form 10. us.rd.yahoo.com |
Aetna Contracts CVS to Run PBM Aetna is contracting out its pharmacy-benefit business to CVS Caremark in a 12-year deal, and the health insurer posted a 42% increase in profit. online.wsj.com |
Elan Holds Tight on Selling Drug Tech Unit The Burrill Report submits: By Michael FitzhughElan (ELN) says it intends to unload $500 million in debt and will delay spinning off its drug delivery technology unit for now in light of poor market conditions. The current market is “not conducive to an appropriate valuation” of Elan Drug Technologies, the company says, noting that it is pleased with the unit’s “strong performance” and the recent launch of Ampyra, a multiple sclerosis drug dispersed using Elan’s technology, with partner Acorda Therapeutics. Complete Story » seekingalpha.com |
The Orthopaedic & Spine Institute. - Video Close-Up TV News recognizes the Orthopaedic & Spine Institute for its remarkable commitment to quality care, providing relief to thousands of patients. feedproxy.google.com |
Look Beyond the Botched Buyout Process for Savient's Value Stone Fox Capital submits:Savient (SVNT) refused to provide information on the failed buyout process on its Tuesday conference call. So investors were left guessing at the interest level. On the one hand, it's understandable that management doesn't want to discuss details in order to not hurt their hand in future discussions. On the other hand, they need to do something better to support the stock price and shareholders. Management should provide some expectations on sales price, since they apparently aren't willing to sell the company to the highest bidder. The company is leaving too much open for interpretation and the market has spoken that it's not acceptable. Having said that, I was pleased to hear the company has made a lot of progress towards the launch of [gout drug treatment] KRYSTEXXA. Savient already has the initial product labeled and ready. Marketing materials are waiting for approval from the FDA. One of the largest private payers has already agreed to include it as a reimbursable cost without knowing its price. The company also expects limited costs to develop the infrastructure needed for the launch.Complete Story » seekingalpha.com |